Abstract
The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was developed at a single center to predict outcomes for allogeneic transplant recipients who have comorbidities. The HCT-CI has not been widely validated in unselected transplant recipients. We evaluated whether the HCT-CI and other readily available pre-transplant variables predicted NRM and OS at a Canadian transplant center. Using a prospective cohort design, we analyzed consecutive adult allogeneic HCT recipients. Of 187 patients, HCT-CI risk was low in 22 (12%), intermediate in 50 (27%), high in 104 (55%) and undetermined in 11 (6%). Two-year OS was 45% (95% CI: 24–64%), 55% (95% CI: 40–68%) and 42% (95% CI: 32–51%) in the low, intermediate and high-risk HCT-CI groups, respectively. Two-year NRM was 36% (95% CI: 17–56%), 26% (95% CI: 15–39%) and 30% (95% CI: 22–39%) in the low, intermediate and high-risk HCT-CI groups, respectively. In multivariate analysis, the HCT-CI failed to predict OS or NRM. However, KPS of <90% at HCT was a strong predictor of NRM. In conclusion, the HCT-CI was not associated with NRM or OS. In contrast, KPS was an independent indicator of survival. International multi-center studies are required before the HCT-CI is used in clinical practice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Charlson ME, Pompei P, Ales KL, MacKenzie CR . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.
Birim O, Maat AP, Kappetein AP, van Meerbeeck JP, Damhuis RA, Bogers AJ . Validation of the charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J Cardiothorac Surg 2003; 23: 30–34.
Birim O, Kappetein AP, Bogers AJ . Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cardiothorac Surg 2005; 28: 759–762.
Fried L, Bernardini J, Piraino B . Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 2001; 37: 337–342.
Murray SB, Bates DW, Ngo L, Ufberg JW, Shapiro NI . Charlson index is associated with one-year mortality in emergency department patients with suspected infection. Acad Emerg Med 2006; 13: 530–536.
Olsson T, Terent A, Lind L . Charlson comorbidity index can add prognostic information to rapid emergency medicine score as a predictor of long-term mortality. Eur J Emerg Med 2005; 12: 220–224.
Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA- matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961–968.
Goldstein LB, Samsa GP, Matchar DB, Horner RD . Charlson index comorbidity adjustment for ischemic stroke outcome studies. Stroke 2004; 35: 1941–1945.
Hemmelgarn BR, Manns BJ, Quan H, Ghali WA . Adapting the Charlson comorbidity index for use in patients with ESRD. Am J Kidney Dis 2003; 42: 125–132.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.
Sorror ML, Giralt S, Sandmaier B, Maris M, Maloney D, Deeg HJ et al. Validation of the predictive power of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for non-relapse mortality (NRM) and survival after allogeneic HCT. Biol Blood Marrow Transplant 2006; 12 (Suppl 1): 8–9.
Kovacsovics T, Hayes-Latin B, Riegert K . Validation of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for nonrelapse mortality (NRM) and survival after matched unrelated donor SCT. Biol Blood Marrow Transplant 2007; 13: 94.
Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110: 4606–4613.
Maruyama D, Fukuda T, Kato R, Yamasaki S, Usui E, Morita-Hoshi Y et al. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduce-intensity regimen. Biol Blood Marrow Transplant 2007; 13: 932–941.
Lim ZY, Ho AYL, Ingram W, Kenyon M, Pearce L, Czepulkowski B et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 2006; 135: 201–209.
Charalampopoulou A, Petridou E, Spyridopoulos T, Dessypris N, Oikonomou A, Athanasiadou-Piperopoulou F et al. An integrated evaluation of socioeconomic and clinical factors in the survival from childhood acute lymphoblastic leukaemia: a study in Greece. Eur J Cancer Prev 2004; 13: 397–401.
Bernheim SM, Ross JS, Krumholz HM, Bradley EH . Influence of patients′ socioeconomic status on clinical management decisions: a qualitative study. Ann Fam Med 2008; 6: 53–59.
Conway DI, Petticrew M, Marlborough H, Berthiller J, Hashibe M, Macpherson LM . Socioeconomic inequalities and oral cancer risk: a systematic review and meta-analysis of case–control studies. Int J Cancer 2008; 122: 2811–2819.
Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 954–964.
Boeck S, Hinke A, Wilkowski R, Heinemann V . Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 2007; 13: 224–227.
Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992–2001.
Carson KA, Grossman SA, Fisher JD, Shaw EG . Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy cns consortium phase I and II clinical trials. J Clin Oncol 2007; 25: 2601–2606.
Firat S, Bousamra M, Gore E, Byhardt RW . Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52: 1047–1057.
Showalter TN, Andrel J, Andrews DW, Curran Jr WJ, Daskalakis C, Werner-Wasik M . Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys 2007; 69: 820–824.
Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550–1558.
Lasser KE, Himmelstein DU, Woolhandler S . Access to care, health status, and health disparities in the United States and Canada: results of a cross-national population-based survey. Am J Public Health 2006; 96: 1300–1307.
Bone Marrow Transplantation: International Comparisons of Availability and Appropriateness of Use. General Accounting Office. 1994; Report No. PEMD-94-10. Accessed online 30 June 2008; http://frwebgate.access.gpo.gov/cgi-bin/useftp.cgi?IPaddress=162.140.64.21&filename=pe94010.txt&directory=/diskb/wais/data/gao.
Kovacsovics T, Park B, Hayes-Lattin B . Applying the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in myeloablative MUD transplants predicts NRM and OS using a modified 2-group scoring system. Biol Blood Marrow Transplant 2008; 14: 105–106.
Acknowledgements
We are grateful to the Leukemia Lymphoma Society of Canada for financially supporting this project. We thank the nursing staff at Winnipeg Health Sciences Centre and CancerCare Manitoba for their excellent patient care.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guilfoyle, R., Demers, A., Bredeson, C. et al. Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 43, 133–139 (2009). https://doi.org/10.1038/bmt.2008.300
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.300
Keywords
This article is cited by
-
Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2024)
-
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older
Bone Marrow Transplantation (2023)
-
Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation
Bone Marrow Transplantation (2022)
-
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
Journal of Hematology & Oncology (2017)
-
Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2016)